Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
35 /100
COMPONENT-LIMITED
Score updated Sep 12, 2026

BCYC — Bicycle Therapeutics plc Dilution Risk Tracker

Track BCYC dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track BCYC — Get alerts when the score changes →

As of September 12, 2026, Bicycle Therapeutics plc (BCYC) has a DilutionWatch DilutionScore of 35/100, rated MEDIUM dilution risk. This is a component-limited score because one or more material inputs are unavailable or not applicable. Bicycle Therapeutics plc has a market capitalization of $327.41M, 30.04M shares outstanding, 100 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
25
📊Float Risk
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for BCYC.
🔔 Track BCYC — Get forecast alerts →

Market Data

Market Cap$327.41M
Shares Outstanding30.04M
FloatN/A
Cash$510.05M
Debt$30.91M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore35/100DilutionWatch score record
Shares Outstanding30.04MVerified float table or market cache
Public FloatNot availableVerified float table or market cache
Market Cap$327.41MMarket data cache
Cash Runway22.7 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 6.

Recent SEC source mix: 4 5, XBRL 1.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 0.9% shares (2026Q1 vs prior)
100 institutional holders · 40.56M shares
#1 BAKER BROS. ADVISORS LP 10.89M shares
#2 FCPM III SERVICES B.V. 3.47M shares
#3 ARMISTICE CAPITAL, LLC 3.40M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest3.28M
Days to Cover13.8
% of FloatN/A
FINRA data as of Aug 31, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2019-12-31
4 INSIDER TRANSACTION 2026-04-06
4 INSIDER TRANSACTION 2026-04-06
4 INSIDER TRANSACTION 2026-04-06
4 INSIDER TRANSACTION 2026-04-06
Full SEC filing analysis available with free account

Recent News

No recent news

Factual BCYC Dilution Snapshot

Bicycle Therapeutics plc (BCYC) has a DilutionScore of 35/100, rated Medium dilution risk. Score date: September 12, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track BCYC Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking BCYC — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,348+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations

Score Coverage Note

More Research for BCYC
BCYC FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.